Edge Therapeutics Культура компании

Mr. Daniel Brennan, also known as Dan, has been Chief Operating Officer at Edge Therapeutics, Inc. since October 17, 2016. Mr. Brennan is responsible for the pre-commercial planning and market development activities including the health economic assessment of its lead product candidate EG-1962, business development activities and general corporate operations within Edge. He has extensive commercial background with orphan, central nervous system (CNS), and hospital products. He has 20 years of senior-level management, commercial and business development experience in the biopharmaceutical industry. He served as the Chief Operating Officer and Executive Vice President of INSYS Therapeutics, Inc. since November 1, 2015 until August 10, 2016. He has had a distinguished career in the pharmaceutical industry. He serves as Vice President and General Manager of Neurology and Business Development for Lundbeck US. He served at Abbott Laboratories where he led Abbott's Hospital Product Pharmaceutical Group. Mr. Brennan earned sales, marketing and new product development expertise from his decade of service at Eli Lilly and Company. He has been a Director of Illinois Biotechnology Industry Organization since December 10, 2014 and the Executive Board of Directors for Court Appointed Special Advocates (CASA) in Lake County, IL. Mr. Brennan received a B.A. from the University of Notre Dame and an MBA degree from the Kellogg Graduate School of Business at Northwestern University.

Dr. R. Loch MacDonald, M.D., Ph.D., is the Co-Founder and Chief Scientific Officer of Edge Therapeutics, Inc. since 2008. Dr. Macdonald is widely considered as a top expert in the world on cerebral vasospasm. His 20 years of unrelenting research has led Edge Therapeutics to its first product, NimoGel, to cure vasospasm. Recent articles published by Dr. Macdonald are Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1), Management of cerebral vasospasm, Prognostic Factors for Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage and Voltage-gated K+ channel dysfunction in myocytes from a dog model of subarachnoid hemorrhage. He has published over 400 articles on the topic of cerebral vasospasm, authored textbooks and written numerous book chapters on the topic. He is a frequent speaker worldwide on the topic of cerebral vasospasm. Prior to becoming Chair at St. Michael's Hospital, he was Professor of Surgery and Radiation & Cellular Oncology at the University of Chicago Medical Center. He has been a Director of Edge Therapeutics, Inc. since 2009. He completed medical school at the University of British Columbia, Vancouver, British Columbia, Canada and completed his Ph.D., (Experimental Surgery), at the University of Alberta, Edmonton, Alberta, Canada, under the guidance of Dr. Bryce Weir. Following his Ph.D. Dr. Macdonald completed his Neurosurgery residency at the University of Toronto, Toronto, Ontario, Canada.

Mr. Andrew Saik has been Chief Financial Officer of Edge Therapeutics, Inc. since November 2017. Mr. Saik served as Chief Financial Officer of Vertice Pharma, LLC since November 2015 until July 2017. Mr. Saik served as the Chief Financial Officer at Auxilium Pharmaceuticals Inc. from August 18, 2014 to January 29, 2015. Mr. Saik was responsible for all financial and information technology activities and relationships and play a critical leadership role in executing Auxilium's diversification and growth strategy. He served as Senior Vice President, Finance and Treasurer at Auxilium Pharmaceuticals Inc (f/k/a Endo Health Solutions Inc.), where he was responsible for internal and external reporting, global consolidations of M&A transactions, cash management, debt financing and risk management. He has 20 years of hands-on experience, including shaping financial strategy, leading successful M&A transactions, integrating global company and product acquisitions and cash management. Prior to Auxilium Pharmaceuticals, Mr. Saik served in senior financial management roles with progressive responsibility at Valeant Pharmaceuticals International (f/k/a ICN Pharmaceuticals Inc.) from January 2001 to July 2002, where he served as its Senior Vice President of Finance and was the overall finance lead for the acquisition and integration of the Johnson & Johnson and Sanofi-Aventis dermatology business units in the U.S. and Canada, enabling Valeant to build the largest dermatology business in North America. Previously at Valeant, he served as Chief Financial Officer of the $1.5 billion Specialty Pharmaceuticals Division which included the U.S., Canada and Australia. Mr. Saik was a finance manager and analyst at Nexgenix, Inc. from October 1999 to January 2001 and the Atlantic Richfield Corporation from June 1996 to October 1999. He holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.

Dr. Herbert J. Faleck, D.O., has been the Chief Medical Officer of Edge Therapeutics, Inc. since August 2013. Dr. Faleck is a pediatric neurologist, has more than 25 years of experience in clinical research. Prior to joining Edge, he was the Chief Medical Officer of Celgene Cellular Therapeutics where he led the clinical, medical, regulatory and organizational development for a key division of Celgene Corporation. He joined Celgene in 2000 as Vice President of Clinical Research and Development and was responsible for several therapeutic areas including hematology/oncology and inflammation as well as the clinical programs that resulted in the approval of several of Celgene's key products. Previously, he held positions of increasing responsibility at Novartis Pharmaceuticals.

Brad Middlekauff serves as the Senior Vice President, General Counsel and Secretary of Edge Therapeutics, Inc.. Brad started at Edge Therapeutics, Inc. in October of 2015. Brad currently resides in Greater New York City Area.

Alyssa Wyant serves as the Senior Vice President, Regulatory Affairs of Edge Therapeutics, Inc.. Alyssa started at Edge Therapeutics, Inc. in February of 2017. Alyssa currently resides in Greater New York City Area.

Carrie DAndrea serves as the Vice President Clinical Operations of Edge Therapeutics, Inc.. Carrie started at Edge Therapeutics, Inc. in June of 2014. Carrie currently resides in Greater New York City Area.

Harry Sacks serves as the Vice President Clinical Development of Edge Therapeutics, Inc.. Harry started at Edge Therapeutics, Inc. in June of 2016. Harry currently resides in Greater Philadelphia Area.

Bert Marchio serves as the Chief Accounting and Administrative Officer; Interim CFO of Edge Therapeutics, Inc.. Bert started at Edge Therapeutics, Inc. in October of 2011. Bert currently resides in the Greater New York City Area.